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New genetic abnormalities affecting risk assess-ment and patient stratification have been reportedin B-cell precursor (BCP) acute lymphoblastic
leukemia (ALL) defining novel subtypes. Some of these
subtypes have been included in the most recent World
Health Organization classification.1 Almost 10 years ago,
two independent studies identified a subset of pediatric
ALL characterized by a specific gene expression profile
similar to that of Philadelphia (Ph) chromosome-positive
ALL.2,3 This novel ALL subtype, called Ph-like ALL or
BCR-ABL1-like ALL, is a frequent ALL subtype that com-
prises up to 15% of pediatric BCP-ALL. Its incidence
reaches 25% in adolescents and young adults and 20% in
adults and it is generally recognized as being associated
with a poor prognosis at any age.4
Ph-like ALL is characterized by multiple genetic aberra-
tions that converge on tyrosine kinase and cytokine
receptor signaling pathways.5 According to the signaling
pathway involved several subgroups have been defined.
These include CRLF2 rearrangements or mutations,
fusions involving ABL-class genes, Ras signaling path-
ways and other less common fusions. Alterations in the
CRLF2 gene are the most frequent and result in overex-
pression of this gene and an increase of CRLF2 protein
expression. Aberrant CRLF2 expression frequently co-
occurs with JAK activating mutations or other mutations
deregulating JAK/STAT signaling (e.g., IL7R mutations).
Deregulation of JAK/STAT signaling may also be due to
JAK2 or EPOR rearrangements or  additional alterations
activating other JAK/STAT signaling genes. In turn, the
subgroup of ABL-class fusions involving ABL1, ABL2,
CSF1R and PDGFRB accounts for 15-20% of Ph-like ALL
cases.
Since kinase-activating alterations are frequent in Ph-
like ALL and most converge on clinically actionable sig-
naling, there is great interest in the early identification of
Ph-like patients, with the aim of improving the prognosis
with the use of tyrosine kinase inhibitors (TKI). However,
identification of Ph-like ALL is currently challenging, and
appropriate assays are not yet available for use as routine
diagnostic approaches.6
In this issue of Haematologica, Chiaretti et al. screened
88 BCP-ALL cases negative for the major fusion genes
(BCR-ABL1, ETV6-RUNX1, TCF3-PBX1 and KTM2A)
enrolled in the pediatric-inspired, measurable residual dis-
ease (MRD)-driven GIMEMA LAL1913 front-line proto-
col for adults with Ph-negative ALL in order to assess
response to the treatment and prognosis.7 Twenty-eight
of these 88 cases (31.8%) showed the Ph-like phenotype.
Screening for Ph-like ALL was performed successfully
using the “BCR/ABL1-like predictor” developed by the
GIMEMA Group.8 This model is based on the identifica-
tion of nine genes specifically overexpressed by adult Ph-
like ALL cases and uses their expression values together
with CRLF2 transcript quantification by real time quanti-
tative polymerase chain reaction to build this predictive
tool. This study showed that Ph-like patients had a lower
complete response rate, event-free survival and disease-
Editorials
1514 haematologica | 2021; 106(6)
Philadelphia chromosome-like acute lymphoblastic leukemia. Still a pending matter 
Josep-Maria Ribera
Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Badalona and Universitat
Autònoma de Barcelona, Spain
E-mail: JOSEP-MARIA RIBERA - jribera@iconcologia.net
doi:10.3324/haematol.2020.270645
Table 1. Clinical trials either specific for Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL patients) or including patients with
Ph-like ALL*.
NCT number                          Group                               Schedule                       Phase                       N patients                       Age (yrs)                     Status
                                                                                                                                                    planned or enrolled 
02883049                                        COG                                      Dasatinib                                3                                      5,956                                      1-30                Active, not recruiting
                                                                                                        Ruxolitinib
02723994                                        COG                                     Ruxolitinib                               2                                        170                                        1-21                          Recruiting
03117751                                       SJCRH                                     Dasatinib                               2/3                                    1,000                                      1-18                          Recruiting
                                                                                                        Ruxolitinib
02420717                                      MDACC                                    Dasatinib
                                                                                                        Ruxolitinib                               2                                         92                                         ≥10                 Active, not recruiting
03571321                         University of Chicago                      Ruxolitinib                               1                                         15                                        18-39                         Recruiting
03643276                                  AIEOP/BFM                              Bortezomib                              3                                      5,000                                       ≤17                          Recruiting
                                                                                                    Blinatumomab
02716233                         Assistance Publique -                       Imatinib                                 3                                      1,578                                      1-18                          Recruiting
                                             Hôpitaux de Paris
03007147                                        COG                                       Imatinib                                 3                                        700                                        2-21                          Recruiting
                                                      EsPhALL
03564470                             Nanfang Hospital                          Chidamide                               2                                        120                                       14-55                          Unknown
                                                    Guangzhou                                 Dasatinib
*Clinicaltrials .gov. accessed on November 28, 2020. COG: Children’s Oncology Group; SJCRH: Saint Jude Childrens Research Hospital; MDACC: MD Anderson Cancer Center; AIEOP:
Associazione Italiana di Ematologia e Oncologia Pediatrica; BFM: Berlin-Frankfurt-Münster; EsPhALL: European PhALL Consortium; yrs: years.
free survival, as well as greater MRD persistence when
treated with a pediatric-oriented and MRD-driven adult
ALL protocol, thus reinforcing the contention that early
recognition of Ph-like ALL is crucial to refine risk-stratifi-
cation and optimize therapeutic strategies. While some
conflicting results on the prognosis of Ph-like ALL have
been reported in pediatric patients, the results of this
study are concordant with those of other studies per-
formed in adults, uniformly showing a poor prognosis for
this ALL subtype.4,9,10 An important finding of this study is
the correlation between the Ph-like phenotype and the
poor MRD clearance at all the time points analyzed, but
especially at week 10 of the protocol, a time point used
for the decision to proceed or not to hematopoietic stem
cell transplantation (HSCT) in this trial. In fact, the Ph-like
profile proved to be the only risk factor for MRD positiv-
ity at this time point. This finding is relevant since half of
the patients were considered a priori as standard risk
according to their features at baseline. In addition, Ph-like
ALL patients from this trial showed inferior cytologic
complete response after induction therapy (a feature not
shown in all studies)11 indicating that better induction
therapies are needed for these patients. This study also
suggests that HSCT is beneficial in these cases and should
be pursued at the earliest opportunity in order to increase
event-free survival.
It seems clear that apart from early recognition, the
management of Ph-like ALL patients should be opti-
mized, and many efforts are currently addressed to
improve the results of therapy. These efforts are mainly
focused on the incorporation of targeted therapies and
immunotherapy to the chemotherapy schedules. TKI
inhibitors (e.g., imatinib, dasatinib and ruxolitinib), his-
tone deacetylase inhibitors (e.g., chidamide) and bispecif-
ic monoclonal antibodies (e.g., blinatumomab) are the
compounds most frequently evaluated in clinical trials
(Table 1). However, there is scarce information available
on the results of these approaches. As an example, a
recent retrospective report by Tanasi et al. showed that
the introduction of TKI frontline during consolidation
improved MRD-negative status and was associated with
a 3-year OS of 77% in a small series of 24 adult patients.12
Clinical trials are limited in Ph-like ALL. Regarding pedi-
atric trials, in the ongoing trials of the Children’s Oncology
Group (COG) (clinicaltrials gov. Identifier: NCT028830499
and in the Total Therapy XVII trial of the Saint Jude
Children’s Research Hospital [SJCRH] clinicaltrials gov.
Identifier: NCT03117751),13 patients with National Cancer
Institute (NCI) high-risk characteristics or poor early MRD
response, who are positive for ABL class fusions and JAK
pathway mutations, receive dasatinib and ruxolitinib,
respectively, together with conventional frontline
chemotherapy from consolidation until the end of mainte-
nance therapy. The COG ALL1521 trial (clinicaltrials gov.
Identifier: NCT02723994) is investigating the benefit of
adding ruxolitinib to backbone COG based NCI high-risk
chemotherapy for patients with CRLF2-rearranged ALL. In
the study by the European ALLTogether consortium,
patients with ABL-class fusions at diagnosis receive TKI on
top of chemotherapy from day 15 of induction; HSCT is
indicated in cases with poor MRD response. In the French
CALL-F01 protocol (clinicaltrials gov. Identifier:
NCT02716233), RNA sequencing is performed in all B-
other ALL in case of induction failure or MRD positivity.
Imatinib is given in combination with chemotherapy in the
high-risk group, and HSCT is indicated in poor responders.
The early introduction of TKI in addition to chemotherapy
in ABL-class positive BCP-ALL is planned to be evaluated
within an intercontinental collaborative trial (clinicaltrials
gov. Identifier: NCT03007147) involving the COG and
EsPhALL (European PhALL Consortium) groups.
Clinical trials for AYA and adult patients are even more
limited. Phase I/II trials conducted at the MD Anderson
Cancer Center are testing dasatinib or low doses of rux-
olitinib in combination with hyper-CVAD (cyclophos-
phamide, vincristine, doxorubicin, and dexamethasone)
in relapsed/refractory ALL and ABL-class fusions or
CRLF2/JAK mutations, respectively. Interim data analysis
has demonstrated the safety of these combinations with
limited efficacy.9 A recent phase I trial at the University of
Chicago and other institutions is studying ruxolitinib in
combination with the pediatric-inspired CALBG (Cancer
and Acute Leukemia Group B) 10403 chemotherapy regi-
men in adolescents with newly diagnosed Ph-like ALL
harboring CRLF2/JAK alterations, with a planned phase II
expansion study if safety is demonstrated.
Regarding the election of TKI, there is no clear evidence
of the superiority of dasatinib over imatinib for Ph-like
ALL cases with ABL-class fusions. This comparison is
especially difficult given that the doses of these TKI differ
among trials. Other TKI, such as nilotinib, bosutinib and
ponatinib, are still being investigated as phase I and II tri-
als in pediatric cancers. Since the combination of TKI and
immunotherapy with blinatumomab has proven feasible
and effective in patients with Ph-positive ALL,14 this
approach should be explored in patients with Ph-like ALL
together with reduced-intensity chemotherapy and
HSCT.15,16
There are challenges in the diagnosis of Ph-like ALL
before using targeted therapy in frontline treatment.
Diagnostic technologies such as RNA sequencing and
similar strategies should be implemented in a timely fash-
ion for all “B-other ALL”, but to date appropriate assays
are not yet available as widely recognized diagnostic
approaches.17-19 Furthermore, although ABL-class and JAK-
pathway alterations account for most Ph-like ALL cases,
there are also several alterations involving kinases that are
not inhibited by either TKI or JAK inhibitors. For this sub-
group of Ph-like cases without known targetable lesions
innovative therapies such as immunotherapy could be
useful to reduce the MRD level before MRD-guided
HSCT.20 Nonetheless, all these efforts will undoubtedly
require collaborative international approaches to conduct
successful studies.
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Granulocyte colony-stimulating factor (G-CSF) is acytokine that increases myelopoiesis,1 impairs lym-phopoiesis by inhibiting committed progenitor
cells,2,3 and enhances hematopoietic stem cell (HSC) mobi-
lization.4 The direct effects of G-CSF on purified subpopu-
lation of HSC remained to be delineated. In this issue of
Haematologica, Xie et al.5 investigate the influence of G-CSF
on proliferation and the repopulating potential of myeloid-
biased, long-term HSC (CD201+CD150+CD48–CD41–
CD34–KSL) and lymphoid-biased, short-term HSC
(CD201+CD150–CD48–CD41–CD34–KSL).  
Understanding the direct influences of G-CSF on HSC
could improve our understanding of HSC responses to an
increase in G-CSF level caused by inflammation.6 The
study by Xie et al. shows that G-CSF acts directly on lym-
phoid-biased, short-term HSC but not on myeloid-biased
HSC. Interestingly, G-CSF cooperates with stem cell fac-
tor in driving the expansion of lymphoid-biased, short-
term HSC in culture and in maintaining the in vivo repop-
ulating potential of such cultures. These findings suggest
that G-CSF-mediated effects on lymphoid-biased, short-
term HSC may contribute to the previously noted
enhancement of early lymphopoiesis of bone marrow
stem and progenitor cells after exposure to G-CSF.7 In
contrast, however, G-CSF is also known to instruct bone
marrow stromal cells to suppress the function of commit-
ted progenitors of B-lymphopoiesis.2 The functional rele-
vance of the G-CSF-mediated priming of early lymphoid
progenitor cells and lymphoid-biased HSC5,7 in associa-
tion with G-CSF-mediated impairment in the progression
of lymphopoiesis from committed progenitor cells2
should be delineated in future studies. 
The primary role of G-CSF is currently seen in activa-
tion of myelopoiesis to strengthen myeloid immune
responses, such as the recruitment of neutrophils during
bacterial lung infections.8 However, the simultaneous
priming of early lymphoid progenitor cells and lymphoid-
biased HSC by G-CSF may also be important to ensure
prompt reactivation of lymphopoiesis after the initial
induction of myeloid cell-driven immune responses. The
sequential coordination of such immune actions by G-
CSF seems to be an interesting area of future research.
Understanding direct influences of G-CSF on HSC
could also be relevant for our understanding of HSC
Granulocyte colony-stimulating factor acts on lymphoid-biased, short-term hematopoietic
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